NCT07321678

A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Ascletis Pharma (China) Co., Limited · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This randomized, double-blind, placebo-controlled Phase II study is designed to evaluate the efficacy, safety, and tolerability of ASC30 oral tablets formulation in participants with Type 2 Diabetes Mellitus

Conditions

• T2DM (Type 2 Diabetes Mellitus)

Interventions

Type	Name	Description
DRUG	ASC30 tablets	ASC30 tablets administered orally once daily
DRUG	Placebo	Placebo administered orally once daily

Timeline

• Start date: 2026-01-01
• Primary completion: 2026-08-01
• Completion: 2026-08-01
• First posted: 2026-01-07
• Last updated: 2026-01-07

Locations

8 sites across 1 country: United States

Regulatory

• FDA-regulated drug study